PRQR

ProQR Therapeutics N.V.

2.07 USD

Last updated Sep 4, 20:37 UTC

Yesterday HIGH

$2.18

Yesterday LOW

$2.07

52w HIGH

$3.1

52w LOW

$1.34

EPS

-0.09

PE

-23.00

Next Earnings

Nov 5, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

ProQR Therapeutics N.V. stock is up 5.08% since 30 days ago. The next earnings date is Nov 5, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 12 September’s closed higher than August. In the last 1 Unusual Options Trades, there were 1 CALL. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

24 Aug 14:44	18 Sep, 2026	2.50	CALL	1400	1559

Advanced Data Unlock

Benzinga Newsdesk

Mon Jun 29, 2026

Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6

Evercore ISI Group analyst Gavin Clark-Gartner maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperform and raises the price target from $5 to $6.
Avi Kapoor

Fri Jun 26, 2026

ON Semiconductor To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday

Top analysts change outlook on top names: BMO, Chardan, Rosenblatt, Susquehanna, Evercore, Deutsche Bank, Baird, Stephens & Co.
Benzinga Newsdesk

Fri Jun 26, 2026

Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $4 to $3.
Benzinga Newsdesk

Thu Jun 25, 2026

ProQR Therapeutics shares are trading lower after the company priced a $50 million underwritten registered direct offering.
Vandana Singh

Thu Jun 25, 2026

Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success

ProQR reported positive AX-0810 Phase 1 data and raised $50 million, with Eli Lilly joining a concurrent share purchase.
Benzinga Newsdesk

Thu Jun 25, 2026

ProQR Therapeutics Prices Registered Direct Offering Of 27,624,310 Shares At $1.81 Per Share For Total Gross Proceeds Of ~$50M; Also Enters Private Placement With Lilly For ~5.1M Shares At Same Offer Price

ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology
Benzinga Newsdesk

Thu Jun 25, 2026

ProQR Therapeutics Announces Data From Its Ongoing Phase 1 Clinical Study Of AX-0810 Investigational Axiomer RNA Editing Oligonucleotide; Sees Target Engagement On All Key Biomarkers

Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the evaluable 3 mg/kg and 6 mg/kg cohortsAX-0810 demonstrated up to 8-fold change
Benzinga Newsdesk

Tue May 12, 2026

ProQR Therapeutics Q1 EPS $(0.15), Inline, Sales $2.381M Miss $5.530M Estimate

ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.10) per share from the same period last year.
Benzinga Newsdesk

Wed Apr 8, 2026

ProQR Therapeutics Announces Key Updates During Virtual Event; Emphasizes Expansion Of Pipeline With Two New Programs And Leading RNA Editing Program On Track For Target Engagement Data
Benzinga Newsdesk

Wed Apr 8, 2026

ProQR Therapeutics Collaborates With Ginkgo Bioworks Over Access To 50+ Instrument Autonomous Lab Nebula

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced its AI

Bank of America

Thu Aug 20, 14:03

buy

initial

Advanced Data Unlock

NFLX $78.29 USD

SNDK $1,738.83 USD

BETR BETR $14.46 USD

ASML $1,714.70 USD

TSLA $353.91 USD

NTLA $12.75 USD

MSTX MSTX $16.80 USD

AZN $162.67 USD

IREN $44.64 USD